

**Form 51-102F3**  
**MATERIAL CHANGE REPORT**

- Item 1. Name and Address of Reporting Issuer
- Global Care Capital Inc. (the “**Company**” or “**Global Care**”)  
Suite 810 - 789 West Pender Street  
Vancouver, BC  
V6C 1H2
- Item 2. Date of Material Change
- April 17, 2020
- Item 3. News Release
- A news release was disseminated on April 20, 2020 through GlobeNewswire and subsequently filed on SEDAR and CSE disclosure hall.
- Item 4. Summary of Material Changes
- The Company announced that it has closed the acquisition of ViralClear Rapid Test Corp. (d/b/a ViraxClear).
- Item 5. Full Description of Material Change
- The Company announced that it has closed the acquisition of ViralClear Rapid Test Corp. (d/b/a ViraxClear) in accordance with a share exchange agreement signed by the Company and ViraxClear on April 15, 2020 (the “**Agreement**”).
- Pursuant to the Agreement, Global Care issued 24,000,000 common shares in the capital of Global Care from treasury (each a “**Consideration Share**”) to arm’s length vendors in return for a 100% interest in ViraxClear. Each Consideration Share has an attributed value of \$0.705 per share. At closing, the ViraxClear option holders exchanged their outstanding ViraxClear options (the “**ViraxClear Options**”) for replacement Global Care options (each a “**Global Care Option**”). Each ViraxClear Option was exchanged for a Global Care Option on a 1:1 basis for an aggregate of 2,900,000 Global Care Options. Of the aggregate number of Global Care Capital Options issued, 2,400,000 Global Care Options have an exercise price of \$0.50 per Global Care common share until April 15, 2022; and 500,000 Global Care Options have an exercise price of \$0.20 per Global Care Capital common share until April 15, 2022. Upon completion of the transaction, ViraxClear became a wholly owned subsidiary of the Company.
- Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102
- Not applicable.
- Item 7. Omitted Information
- Not applicable.

Item 8. Executive Officer

For further information, please contact:  
Alexander Somjen  
President and Chief Executive Officer  
Telephone: 416-319-5744

Item 9. Date of Report

April 20, 2020